(Q46959411)

26 December 2017

title

Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice (English)

1 reference

26 December 2017

0 references

Yamanaka M

1

1 reference

26 December 2017

Itakura Y

2

1 reference

26 December 2017

Tsuchida A

3

1 reference

26 December 2017

Nakagawa T

4

1 reference

26 December 2017

Noguchi H

5

1 reference

26 December 2017

Taiji M

6

1 reference

26 December 2017

publication date

1 November 2007

1 reference

26 December 2017

Diabetes, Obesity and Metabolism

published in

1 reference

26 December 2017

volume

9

1 reference

26 December 2017

issue

6

1 reference

26 December 2017

page(s)

879-888

1 reference

26 December 2017

Nerve growth factor and the neurotrophic factor hypothesis

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Neurotrophic factors: from molecule to man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Brain-derived neurotrophic factor reduces blood glucose level in obese diabetic mice but not in normal mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Pathogenesis of NIDDM. A balanced overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Metformin and thiazolidinedione use in Medicare patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

The effects of brain-derived neurotrophic factor on insulin signal transduction in the liver of diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Considerations for management of fluid dynamic issues associated with thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Brain-derived neurotrophic factor ameliorates hepatic insulin resistance in Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Protective effect of brain-derived neurotrophic factor on pancreatic islets in obese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

Brain-derived neurotrophic factor modulates glucagon secretion from pancreatic alpha cells: its contribution to glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00675.X

10.1111/J.1463-1326.2006.00675.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

17924870

1 reference

26 December 2017